X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla Fact Sheet, Cipla Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Cipla Fact Sheet   (CIPL)

Here is the latest financial fact sheet of Cipla. For more details, see the Cipla quarterly results and Cipla share price and chart. For a sector overview, read our pharmaceuticals sector report.

CIPLA Price History

Price Rs 615.0
Mkt Cap Rs m 494,589
Vol '000 4.4
P/E X 45.2
P/CF X 20.9
EPS (TTM) Rs 13.6
% ch % 0.7
No. of shares m 804.21
% ch week % 5.1
% ch 1-mth % 7.9
% ch 12-mth % 4.0
52 week H/L Rs 634.0/479.0
(As on Oct 23, 2017 09:26:00 AM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

CIPLA Financials

No. of Mths
Year Ending
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
5-Yr Chart
Click to enlarge
CIPLA EQUITY SHARE DATA
High Rs435450753748622 
Low Rs301364369495458 
Sales per share (Unadj.) Rs103.1126.7141.3171.7181.9 
Earnings per share (Unadj.) Rs19.217.314.717.212.9 
Diluted earnings per shareRs19.217.314.717.212.9 
Cash flow per share (Unadj.) Rs23.421.921.026.629.3 
Dividends per share (Unadj.) Rs2.002.002.002.002.00 
Adj. dividends per shareRs2.002.002.002.002.00 
Dividend yield (eoy) %0.50.50.40.30.4 
Book value per share (Unadj.) Rs112.3125.2132.6143.3155.7 
Adj. book value per shareRs112.1125.0132.4143.2155.7 
Shares outstanding (eoy) m802.92802.92802.96803.38804.51 
Bonus/Rights/Conversions  --ESOPESOPESOP 
Price / Sales ratio x3.63.24.03.63.0 
Avg P/E ratio x19.123.538.136.142.0 
P/CF ratio (eoy) x15.818.626.723.418.4 
Price / Book Value ratio x3.33.34.24.33.5 
Dividend payout %10.411.613.611.615.5 
Avg Mkt Cap Rs m295,475326,829450,139499,381434,516 
No. of employees `000NANANA24.123.0 
Total wages/salary Rs m10,36015,43019,73724,34026,338 
Avg. sales/employee Rs ThNMNMNM5,723.76,349.1 
Avg. wages/employee Rs ThNMNMNM1,010.31,143.0 
Avg. net profit/employee Rs ThNMNMNM574.2449.3 
CIPLA INCOME DATA
Net Sales Rs m82,793101,734113,454137,901146,302 
Other income Rs m2,2212,6541,6562,0822,287 
Total revenues Rs m85,015104,388115,110139,983148,589 
Gross profit Rs m21,97921,33121,61724,79724,758 
Depreciation Rs m3,3053,7265,0477,54213,229 
Interest Rs m3391,4571,6832,0661,594 
Profit before tax Rs m20,55618,80016,54317,27012,222 
Minority Interest Rs m0-159-48200 
Prior Period Items Rs m-62-123-253-120-70 
Extraordinary Inc (Exp) Rs m3980000 
Tax Rs m5,4434,6344,0003,3161,798 
Profit after tax Rs m15,44913,88411,80813,83410,354 
Gross profit margin %26.521.019.118.016.9 
Effective tax rate %26.524.624.219.214.7 
Net profit margin %18.713.610.410.07.1 
CIPLA BALANCE SHEET DATA
Current assets Rs m67,84056,51475,58288,41287,370 
Current liabilities Rs m22,77625,63637,61877,76133,081 
Net working cap to sales %54.430.433.57.737.1 
Current ratio x3.02.22.01.12.6 
Inventory Days Days10510412210187 
Debtors Days Days7459626262 
Net fixed assets Rs m39,87844,45248,521110,786111,567 
Share capital Rs m1,6061,6061,6061,6071,609 
"Free" reserves Rs m87,81898,591104,847113,555123,645 
Net worth Rs m90,187100,504106,453115,162125,254 
Long term debt Rs m63,1793,0932,21936,454 
Total assets Rs m116,588134,032156,471211,282209,532 
Interest coverage x61.613.910.89.48.7 
Debt to equity ratio x00000.3 
Sales to assets ratio x0.70.80.70.70.7 
Return on assets %13.511.48.67.55.7 
Return on equity %17.113.811.112.08.3 
Return on capital %23.519.316.016.48.5 
Exports to sales %53.548.641.748.534.2 
Imports to sales %15.914.014.712.58.3 
Exports (fob) Rs m44,26249,48047,36366,83750,050 
Imports (cif) Rs m13,16214,26116,62917,27012,203 
Fx inflow Rs m44,94751,49949,10467,46151,066 
Fx outflow Rs m15,90618,94322,48324,72917,678 
Net fx Rs m29,04232,55626,62142,73333,388 
CIPLA CASH FLOW
From Operations Rs m 13,977 15,633 11,734 17,408 23,824 
From Investments Rs m -20,629 -12,499 -9,412 -45,226 -13,127 
From Financial Activity Rs m 7,178 -2,656 1,648 31,041 -13,239 
Net Cashflow Rs m 526 478 3,971 3,123 -2,478 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 16.0%
Foreign collaborators 20.8%
Indian inst/Mut Fund 12.2%
FIIs 23.7%
ADR/GDR 1.1%
Free float 26.2%
Shareholders 161,166
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-13
E-MAIL cosecretary@cipla.com WEB www.cipla.com
TELEPHONE (022) 2482 6000 FAX (022) 2482 6893
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR V. Sankar Aiyar & Co.
CHM: Y. K. Hamied (MD) COMP SEC: Mital Sanghvi YEAR OF INC: 1935 BSE CODE: 500087 FV (Rs): 2 DIV YIELD (%): 0.3

More Pharmaceuticals Company Fact Sheets:   CADILA HEALTHCARE  AMAR REMEDIES  TTK HEALTHCARE  FDC LTD.  ALKEM LABORATORIES  

Compare CIPLA With:   CADILA HEALTHCARE  AMAR REMEDIES  TTK HEALTHCARE  FDC LTD.  ALKEM LABORATORIES  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Views on news

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Timeless Stocks on the Electric Car Assembly Line(The 5 Minute Wrapup)

Oct 10, 2017

Are they on their way to create Coca Cola-like wealth?

Why Merger of Public Sector Banks Continues to Be a Bad Idea(Vivek Kaul's Diary)

Oct 10, 2017

There is enough research evidence that suggests that most mergers don't work.

Electric Vehicles: The Final Piece of the Puzzle(Smart Contrarian)

Oct 16, 2017

Just as there would be gainers from an electric vehicles boom, who possibly could be the biggest losers.

Mutual Funds Re-categorised... But What About Stocks?(Daily Profit Hunter)

Oct 11, 2017

The market regulator can solve systemic issues but you must tackle the behavioral biases on your own.

Companies Are Wary of Borrowing(Chart Of The Day)

Oct 17, 2017

How to profit from behavioral biases afflicting the industry.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK CIPLA

MORE ON CIPLA

CIPLA - FDC LTD. COMPARISON

COMPARE CIPLA WITH

MARKET STATS